[18F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [18F]FDOPA and [11C]DASB PET study in Parkinson's disease

被引:42
作者
Pavese, N. [1 ]
Simpson, B. S. [1 ]
Metta, V. [2 ,3 ,4 ]
Ramlackhansingh, A. [1 ]
Chaudhuri, K. Ray [2 ,3 ,4 ]
Brooks, D. J. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Dept Med, Ctr Neurosci, London, England
[2] Kings Coll London, Natl Parkinson Fdn, Ctr Excellence, London WC2R 2LS, England
[3] Lewisham Hosp NHS Trust, London, England
[4] Kings Coll London, Biomed Res Ctr, London WC2R 2LS, England
基金
英国医学研究理事会;
关键词
Positron emission tomography (PET); F-18]FDOPA; C-11]DASB serotonin Parkinson; Monoamine; Extrastriatal; F-18-DOPA PET; I-123-BETA-CIT SPECT; CONTAINING NEURONS; FLUORODOPA UPTAKE; F-18; FLUORODOPA; MIDBRAIN; DOPAMINE; BINDING; DORSAL; BRAIN;
D O I
10.1016/j.neuroimage.2011.09.034
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Brain uptake of [F-18]FDOPA, measured with PET, reflects the activity of aromatic amino acid decarboxylase, an enzyme largely expressed in monoaminergic nerve terminals. This enzyme catalyzes a number of decarboxylation reactions including conversion of L-dopa into dopamine and 5-hydroxytryptophan into serotonin. For more than 20 years [F-18]FDOPA PET has been used to assess dopaminergic nigrostriatal dysfunction in patients with Parkinson's disease (PD). More recently, however, [F-18]FDOPA PET has also been employed as a marker of serotoninergic and noradrenergic function in PD patients. In this study, we provide further evidence in support of the view that [F-18]FDOPA PET can be used to evaluate the distribution and the function of serotoninergic systems in the brain. Eighteen patients with PD were investigated with both [F-18]FDOPA and [C-11]DASB PET, the latter being a marker of serotonin transport (SERT) availability. We then assessed the relationship between measurements of the two tracers within brain serotoninergic structures. [F-18]FDOPA uptake in the median raphe nuclei complex of PD patients was significantly correlated with SERT availability in the same structure. Trends towards significant correlations between [F-18]FDOPA Ki values and [C-11]DASB binding values were also observed in the hypothalamus and the anterior cingulate cortex, suggesting a serotoninergic contribution to [F-18]FDOPA uptake in these regions. Conversely, no correlations were found in brain structures with mixed dopaminergic, serotoninergic and noradrenergic innervations, or with predominant dopaminergic innervation. These findings provide evidence that [F-18]FDOPA PET represents a valid marker of raphe serotoninergic function in PD and supports previous studies where [F-18]FDOPA PET has been used to assess serotoninergic function in PD. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:1080 / 1084
页数:5
相关论文
共 50 条
[41]   Quantitative Analysis of Amyloid Beta Deposition in the Brain of Alzheimer's Disease Patients Using PET and [11C]BF-227 and [18F]FACT [J].
Tashiro, M. ;
Okamura, N. ;
Watanuki, S. ;
Furumoto, S. ;
Furukawa, K. ;
Funaki, Y. ;
Shibuya, K. ;
Iwata, R. ;
Kudo, Y. ;
Arai, H. ;
Yanai, K. .
6TH WORLD CONGRESS OF BIOMECHANICS (WCB 2010), PTS 1-3, 2010, 31 :1648-+
[42]   Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-L-DOPA and 18F-FDOPA in Parkinson Disease Monkeys [J].
Kanazawa, Masakatsu ;
Ohba, Hiroyuki ;
Harada, Norihiro ;
Kakiuchi, Takeharu ;
Muramatsu, Shin-ichi ;
Tsukada, Hideo .
JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (02) :303-308
[43]   Longitudinal DAT changes measured with [18F]FE-PE2I PET in patients with Parkinson?s disease; a validation study [J].
Kerstens, V. S. ;
Fazio, P. ;
Sundgren, M. ;
Brumberg, J. ;
Halldin, C. ;
Svenningsson, P. ;
Varrone, A. .
NEUROIMAGE-CLINICAL, 2023, 37
[44]   α4β2-nicotinic receptor availability in Parkinson's disease MCI and healthy controls: A pilot imaging study using [18F]-XTRA PET [J].
Mills, K. ;
Du, Y. ;
Coughlin, J. ;
Horti, A. ;
Pomper, M. ;
Smith, G. .
MOVEMENT DISORDERS, 2018, 33 :S649-S650
[45]   Correlating Parkinson's disease motor symptoms with three-dimensional [18F]FP-CIT PET [J].
Chung, Moonyoung ;
Park, Young Seok ;
Kim, Ji Seon ;
Kim, Yun Joong ;
Ma, Hyeo Il ;
Jang, Su Jin ;
Huh, Ryoong ;
Kim, Hyun Sook ;
Kim, Won-Chan .
JAPANESE JOURNAL OF RADIOLOGY, 2015, 33 (10) :609-618
[46]   Subregional 6-[18F]fluoro-L-m-tyrosine Uptake in the Striatum in Parkinson's Disease [J].
Asari, Sayaka ;
Fujimoto, Ken-ichi ;
Miyauchi, Akihiro ;
Sato, Toshihiko ;
Nakano, Imaharu ;
Muramatsu, Shin-ichi .
BMC NEUROLOGY, 2011, 11
[47]   A comparison study of dynamic [18F]Alfatide II imaging and [11C]MET in orthotopic rat models of glioblastoma [J].
Pan, Yue ;
Dang, Haodan ;
Zhou, Haoxi ;
Fu, Huaping ;
Wu, Shina ;
Liu, Huanhuan ;
Zhang, Jinming ;
Wang, Ruimin ;
Tian, Yuan ;
Xu, Baixuan .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (04)
[48]   A Follow-Up Study on 6-[18F]Fluoro-L-dopa Uptake in Early Parkinson's Disease Shows Nonlinear Progression in the Putamen [J].
Bruck, Anna ;
Aalto, Sargo ;
Rauhala, Elina ;
Bergman, Jorgen ;
Marttila, Reijo ;
Rinne, Juha O. .
MOVEMENT DISORDERS, 2009, 24 (07) :1009-1015
[49]   Synthesis and Pharmacological Evaluation of [11C]Granisetron and [18F]Fluoropalonosetron as PET Probes for 5-HT3 Receptor Imaging [J].
Mu, Linjing ;
Herde, Adrienne Muller ;
Ruefli, Pascal M. ;
Sladojevich, Filippo ;
Sephton, Selena Milicevic ;
Kramer, Stefanie D. ;
Thompson, Andrew J. ;
Schibli, Roger ;
Ametamey, Simon M. ;
Lochner, Martin .
ACS CHEMICAL NEUROSCIENCE, 2016, 7 (11) :1552-1564
[50]   Reproducibility of PET studies with L-[β-11C]DOPA and [18F]FE-PE2I in healthy humans [J].
Suzuki, Masayuki ;
Ito, Hiroshi ;
Takano, Harumasa ;
Fujiwara, Hironobu ;
Kimura, Yasuyuki ;
Kodaka, Fumitoshi ;
Varrene, Andrea ;
Okubo, Yoshiro ;
Suhara, Tetsuya .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2012, 32 :S131-S131